Independent
Tenure on this board
10.5 yrs
Meeting calendar
CYPH · Special meeting · Monday, December 15, 2025
Cypherpunk Technologies Inc
10 nominees · 5 ballot items.
The Leap Therapeutics special meeting includes five stockholder proposals: Authorized Share Increase, Reverse Stock Split, Leap 2025 Equity Incentive Plan, Private Placement Issuance (change of control), and Adjournment; board recommends voting FOR all.
Market cap
$348M
1Y TSR
+784.8%
Board grade
C-
Record date
Oct 24, 2025
Filing
DEF 14A
Meeting concluded · Dec 15, 2025
Follow how the vote landed and what changed on Cypherpunk Technologies Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot5
- 1
Approval of Authorized Share Increase Proposal
ShareholderBoard: FORAmend the Charter to increase authorized common stock from 250,000,000 to 500,000,000 shares and to designate 490,000,000 as Common Stock, with clarifying language regarding DGCL Section 242.
- 2
Approval of the Reverse Stock Split Proposal
ShareholderBoard: FORAmend the Charter to permit the Board to effect a reverse stock split in a ratio to be determined within 1:5 to 1:20 within one year of the Special Meeting to regain Nasdaq listing compliance.
- 3
Approval of the Leap Therapeutics, Inc. 2025 Equity Incentive Plan
ShareholderBoard: FORAdopt the Leap Therapeutics, Inc. 2025 Equity Incentive Plan to provide for new awards and include an evergreen feature, subject to stockholder approval.
- 4
Approval of the Issuance of Up to 152,754,109 Shares of Common Stock Pursuant to the Private Placement Issuance Proposal
ShareholderBoard: FORAllow issuance of Common Stock upon exercise of Pre-Funded Warrants and Common Warrants from the Financing Transaction, potentially exceeding 19.99% on a non-discretionary basis under Nasdaq's Change of Control Rule; necessary to complete financing.
- 5
Approval of the Adjournment Proposal
ShareholderBoard: FORAuthorize the board to adjourn the Special Meeting to continue soliciting proxies if necessary.
Director elections
Nominees on the ballot10
Not independent
Tenure on this board
17.8 yrs
Independent
Tenure on this board
9.4 yrs
Independent
Tenure on this board
9.7 yrs
Independent
Tenure on this board
9.8 yrs
Independent
Tenure on this board
9.4 yrs
Also a director at
Ionis Pharmaceuticals Inc (IONS)
Independent
Tenure on this board
9.7 yrs
Independent
Tenure on this board
3.8 yrs
Independent
Tenure on this board
3.7 yrs
Also a director at
An2 Therapeutics Inc (ANTX)
Independent
Tenure on this board
3.7 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 3.6% | 3,887,574 | $2M |
| 2 | BlackRock, Inc. | 2.4% | 2,622,823 | $2M |
| 3 | JANE STREET GROUP, LLC | 1.1% | 1,200,476 | $735K |
| 4 | UBS Group AG | 1.0% | 1,071,847 | $656K |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 0.8% | 873,464 | $535K |
| 6 | CITADEL ADVISORS LLC | 0.8% | 836,153 | $512K |
| 7 | XTX Topco Ltd | 0.6% | 638,329 | $391K |
| 8 | VANGUARD FIDUCIARY TRUST CO | 0.5% | 571,345 | $350K |
| 9 | STATE STREET CORP | 0.5% | 516,113 | $316K |
| 10 | JANE STREET GROUP, LLC | 0.5% | 501,450 | $307K |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Cypherpunk Technologies Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Sanara Medtech IncSMTI
Special meeting·Sep 30, 2026·$322M
Tilray Brands IncTLRY
Annual meeting·Nov 18, 2026·$538M
Weave Communications IncWEAV
Special meeting·Oct 22, 2026·$589M
Varex Imaging CorpVREX
Special meeting·Oct 28, 2026·$778M
Phibro Animal Health CorpPAHC
Annual meeting·Nov 3, 2026·$1.4B
Biolife Solutions IncBLFS
Special meeting·Oct 5, 2026·$1.9B
Reference
Frequently asked questions
- When is the Cypherpunk Technologies Inc 2025 special meeting?
- Cypherpunk Technologies Inc (CYPH) holds its 2025 special shareholder meeting on Monday, December 15, 2025.
- What is the record date for the Cypherpunk Technologies Inc 2025 meeting?
- The record date for the Cypherpunk Technologies Inc 2025 meeting is Friday, October 24, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Cypherpunk Technologies Inc's 2025 meeting?
- The board is presenting 10 director nominees at the Cypherpunk Technologies Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Cypherpunk Technologies Inc 2025 meeting?
- Shareholders will vote on 5 proposals at the Cypherpunk Technologies Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.